We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Less Than 40 Percent of Drugs With Accelerated Approval are of High Therapeutic Value
Less Than 40 Percent of Drugs With Accelerated Approval are of High Therapeutic Value
The FDA’s accelerated approval program has come under fire again, this time from a group of researchers that found only 38.9 percent of new drugs green-lighted via accelerated approval demonstrated high therapeutic value when compared with existing therapies.